Clinical Trial Detail

NCT ID NCT03194893
Title A Roll Over Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Hoffmann-La Roche
Indications

Advanced Solid Tumor

lymphoma

Therapies

Crizotinib

Alectinib

Age Groups: adult senior child

Additional content available in CKB BOOST